Clinical trial Recruiting at 1 site Interventional Ages 18 to 70

Frontopolar tDCS to improve safety learning and extinction in OCD

Official title: Characterization and Modulation of Functional Connectivity and Fear Extinction Abnormalities in Obsessive-Compulsive Disorder

Run by Yale University · NCT06834217 · Data updated 2026-11-12

This will test whether brief frontopolar transcranial direct current stimulation (tDCS) can help adults with OCD improve extinction learning and safety-signal processing.

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment180 (estimated)
SponsorYale University
Academic / other
Locations1 site (New Haven, Connecticut)
StatusRecruiting
StartedSeptember 12, 2025
Main results expectedApril 1, 2029
Study endsAugust 1, 2029
Registry record updatedJuly 23, 2026
Trial IDNCT06834217 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 or older with a primary diagnosis of OCD, at least one year of symptoms, currently symptomatic, and on stable or no psychiatric treatment for at least eight weeks would be eligible.

Probably not a fit

People with bipolar disorder, psychotic disorders, active severe substance use, major neurological disease, significant traumatic brain injury, pregnancy, or other excluded conditions are unlikely to be eligible or to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will enroll 180 adults (120 with OCD, 60 matched controls) for a three-day, in-person experiment combining fMRI, fear-conditioning/extinction tasks, and physiological measures such as skin conductance and threat-expectancy ratings. On day 1 participants undergo structural and resting-state fMRI and Pavlovian conditioning to establish fear and safety cues. On day 2 OCD participants are randomized, double-blind, to receive either active or sham frontopolar tDCS during extinction training. The team will examine whether OCD is linked to dysconnectivity between the default mode and salience networks and whether tDCS normalizes connectivity and improves extinction-related learning and responding.

Why it matters

Potential benefit: If successful, this approach could improve the brain's ability to learn safety during exposure-based treatment and thereby enhance outcomes for people with OCD.

How similar studies have gone: Prior laboratory and small clinical studies have shown that tDCS can modulate learning, memory, and network connectivity, but clinical evidence for lasting benefits in OCD is limited and mixed.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All Participant Inclusion Criteria would include:

  1. 18 years of age or older
  2. speak English fluently, and
  3. able to provide written and verbal informed consent.
* Obsessive-compulsive disorder (OCD) Inclusion Criteria would include:

  1. meet criteria for OCD as determined by structured clinical interview
  2. exhibit significant current symptoms of OCD
  3. report duration of OCD symptoms of at least 1-year
  4. OCD symptoms are primary or co-primary relative to other psychiatric diagnoses
  5. stable psychiatric treatment (≥8-weeks) or no active treatment.
  6. exhibit significant current symptoms of OCD as determined by the Dimensional Obsessive-Compulsive Scale (DOCS) (≥18).

Exclusion Criteria:

* All Participant Exclusion Criteria would include:

  1. active severe substance use disorder(s)
  2. acute suicidality
  3. history of bipolar or psychotic disorder(s)
  4. significant developmental disabilities
  5. loss of consciousness \> 10 minutes
  6. history of traumatic brain injury
  7. major neurological disease
  8. a positive pregnancy test
  9. other brain stimulation or magnetic resonance imaging contraindications
  10. new psychological treatment within the past 8 weeks
  11. daily anxiolytic medication use (e.g., benzodiazepine).
* Non-Clinical Control Exclusion Criteria would include:

  1. meet current criteria for a psychiatric disorder as determined by structured clinical interview
  2. active-psychotropic medications.

Where it's running

  • Temple Medical Center
    New Haven, Connecticut, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.